Back to Newsroom
Back to Newsroom

LAWSUITS FILED AGAINST BMRN, AMRN and CEI - Jakubowitz Law Pursues Shareholders Claims

Wednesday, 03 November 2021 02:45 PM

Jakubowitz Law

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / November 3, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

CONTACT JAKUBOWITZ ABOUT BMRN:
https://claimyourloss.com/securities/biomarin-pharmaceutical-inc-loss-submission-form-2/?id=20861&from=1

Class Period : January 13, 2020 - September 3, 2021

Lead Plaintiff Deadline : December 22, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Phenylalanine Hydroxylase, was less safe than BioMarin had led investors to believe; (ii) BMN 307's safety profile made it likely that the Food and Drug Administration would place a clinical hold on the Phearless Phase 1/2 study; (iii) accordingly, the Company had overstated BMN 307's clinical and commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Amarin Corporation Plc (NASDAQ:AMRN)

CONTACT JAKUBOWITZ ABOUT AMRN:
https://claimyourloss.com/securities/amarin-corporation-plc-loss-submission-form/?id=20861&from=1

Class Period : December 5, 2018 - June 21, 2021

Lead Plaintiff Deadline : December 23, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) there was an increasingly high risk that certain of Amarin's patents would be invalidated; (ii) once the District Court invalidated certain of Amarin's patents, there was little to no chance of reversing that ruling; (iii) the Company's litigation was preventing it from effectuating a successful takeover; (iv) Defendants were downplaying the true threat the ongoing abbreviated new drug application litigation posed to the Company's business and future prospects; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Camber Energy, Inc. (NYSE:CEI)

CONTACT JAKUBOWITZ ABOUT CEI:
https://claimyourloss.com/securities/camber-energy-inc-loss-submission-form/?id=20861&from=1

Class Period : February 18, 2021 - October 4, 2021

Lead Plaintiff Deadline : December 28, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Camber overstated the financial and business prospects of Viking as well as the combined company post merger; (ii) Camber failed to apprise investors of, and/or downplayed, the fact that its acquisition of a controlling interest in Viking would exacerbate the Company's delinquent financial statements and listing obligations with the NYSE; (iii) an institutional investor was diluting Camber's shares at a significant rate following the Company's July 12, 2021 update regarding the number of its shares of common stock issued and outstanding; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Jakubowitz Law, Wednesday, November 3, 2021, Press release picture

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: